20 July 2020

British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies

20 July 2020

SV Health Investors hits $265m final close for first dedicated biotech fundraiseRead More

1 July 2020

Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health

8 June 2020

SV listed 6th in "The Top 50 Most Active Venture Capital Firms in Boston"Read More

27 May 2020

COVID-19's 'unprecedented stress' on social services drives demand for innovative SDOH programs

1 May 2020

How the UK life sciences industry is rising to the challenge of Covid-19 by Kate Bingham

• 
  23 July 2020Portfolio News

  Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
• 20 July 2020SV News

  British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies
• 
  23 June 2020Portfolio News

  Alchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK
• 
  17 June 2020Portfolio News

  Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
• 
  27 April 2020Portfolio News

  Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer to lead XTX201 (tumor-selective IL-2) and XTX101 (tumor-Selective aCTLA-4) into the clinic while xilio continues to advance its tumor-selective cytokine pipeline

---